1. Andrews M, Behren A, Chiohn F, Tebbutt N, Do H, Dobrovic A, Mariadason J, Cebon J (2012) Colorectal cancer promoted in a melanoma patient receiving dabrafenib (GSK2118436) in combination with MEK1/2 inhibitor trametinib (GSK1120212). Pigment Cell Melanoma Res 25: 842.
2. Ascierto PA, Minor D, Ribas A, Lebbe C, O'hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob J-J, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin A-M, Mazumdar J, Goodman VL, Trefzer U (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31: 3205–3211.
3. Bollag G (2012) New strategies for mutation-specific targeting of oncogenic kinases. 103rd Annual Meeting of the American Association for Cancer Research; 31 March—4 April 2012; AACR: Chicago, IL, USA.
4. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, Thomas M, Vagner S, Favre M, Tomasic G, Wechsler J, Lacroix L, Robert C (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24: 1691–1697.
5. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367: 2316–2321.